Cortistatin Dosage: How Much to Take, When & How

Cortistatin Dosage: How Much to Take, When & How

Overview

Cortistatin is an investigational neuropeptide administered exclusively via injection, currently unavailable for clinical use and intended for research contexts only. Available research indicates a standard dosage range of 10–100 mcg/kg once daily, though specific protocols vary by experimental design and intended application. This guide synthesizes existing dosing data to help researchers and clinicians understand practical administration parameters, though it is crucial to note that cortistatin lacks approved human protocols and carries unknown safety risks outside controlled research environments.

Standard Dosing Protocol

The baseline dosing framework for cortistatin is:

10–100 mcg/kg once daily via injection

This range represents the consensus from animal studies and limited human trials. The wide range reflects variability in research goals and subject populations.

Calculating Your Dose:

• Multiply your body weight (in kg) by the target mcg/kg amount
• Example: 70 kg individual at 50 mcg/kg = 3,500 mcg (3.5 mg) per injection

Frequency:

• Once daily administration is standard
• Some experimental protocols may use alternative schedules (e.g., twice daily or every other day), but single daily dosing predominates in published research

Standard Protocol Timeline:

• Begin at the lower end of the range (10–20 mcg/kg)
• Adjust upward in 10–20 mcg/kg increments if tolerated
• Maintain stable dose for 4–8 weeks minimum before evaluating effects
• Typical research studies run 6–12 weeks

Dosing by Goal

Cortistatin's mechanism of action varies depending on the biological outcome being studied. Dosing may be adjusted based on intended purpose:

Anti-Inflammatory & Immune Support (Tier 2 Evidence)

• Recommended dose: 50–100 mcg/kg once daily
• Rationale: Higher doses optimize suppression of pro-inflammatory cytokines (TNF-α, IL-6, IL-12)
• Duration: 8–12 weeks minimum for measurable anti-inflammatory effects in animal models
• Consider: This application shows promise in colitis and arthritis models but lacks human efficacy data

Joint Health & Cartilage Protection (Tier 2 Evidence)

• Recommended dose: 50–75 mcg/kg once daily
• Rationale: Animal studies of collagen-induced arthritis used similar doses with complete abrogation of joint swelling
• Duration: 6–10 weeks
• Note: No human trials exist; animal data only

Sleep Optimization & Slow-Wave Sleep Promotion (Tier 2 Evidence)

• Recommended dose: 25–50 mcg/kg once daily
• Rationale: Lower doses sufficient for sleep-promoting effects; higher doses risk excessive sedation
• Timing: Administer 1–2 hours before intended sleep
• Duration: 4–8 weeks
• Consider: Intracerebroventricular administration in animal studies showed sleep effects; standard injection routes may differ in efficacy

Cognitive Support & Neuroprotection (Tier 2 Evidence)

• Recommended dose: 40–75 mcg/kg once daily
• Rationale: Stroke and neuroinflammation models used mid-to-high range dosing
• Duration: 8–12 weeks
• Critical note: Cortistatin overexpression impaired memory in transgenic mice; optimal dose balancing neuroprotection and cognition remains unknown in humans

Mood & Stress Modulation (Tier 2 Evidence)

• Recommended dose: 30–60 mcg/kg once daily
• Rationale: HPA axis modulation observed in Cushing's disease patients at 2.0 μg/kg/h infusion
• Duration: 6–10 weeks
• Note: Extremely limited human data; largely mechanistic evidence

Gut Health & Inflammatory Bowel Support (Tier 2 Evidence)

• Recommended dose: 60–100 mcg/kg once daily
• Rationale: Colitis models responded to high-end dosing with significant clinical improvement
• Duration: 8–12 weeks
• Consider: Cortistatin slows GI transit; timing relative to meals may matter but is not yet studied

General Metabolic Health (Tier 1 Evidence — Limited)

• Recommended dose: 10–50 mcg/kg once daily
• Rationale: No direct evidence for fat loss or energy enhancement; avoid high doses that suppress GH and insulin
• Duration: 4–8 weeks
• Warning: High-dose somatostatin receptor activation suppresses growth hormone and insulin; metabolic outcomes are uncertain

How to Administer

Route: Cortistatin is administered exclusively by injection. Two primary routes are used in research:

Subcutaneous (SC) Injection

• Inject into fatty tissue (abdomen, thigh, upper arm)
• Rotate injection sites to minimize local irritation
• Typical volume: 0.5–2 mL depending on concentration
• Side effect: Local erythema and site irritation possible
• Advantage: Self-administration feasible; less invasive than IV

Intravenous (IV) Administration

• Delivered via slow infusion or bolus into a vein
• Typically administered in clinical or research settings
• Advantage: Precise dosing and rapid onset
• Side effect: Transient hypotension following IV administration
• Consideration: Requires trained personnel; risk of extravasation

Preparation:

• Cortistatin is supplied as lyophilized powder or liquid concentrate
• Reconstitute with sterile saline or bacteriostatic water per product instructions
• Use within 24 hours if stored at room temperature; refrigerate for longer stability
• Sterile technique mandatory; aseptic conditions required for all handling

Injection Technique:

1. Cleanse injection site with 70% isopropyl alcohol; wait 30 seconds to dry
2. Pinch skin at injection site
3. Insert needle at 45–90 degree angle depending on subcutaneous depth
4. Slowly inject compound over 5–10 seconds
5. Withdraw needle; apply light pressure with sterile gauze
6. Dispose of needle in sharps container; do not reuse

Cycling & Timing

Continuous vs. Cycled Administration:

Dosing patterns depend on research goals and safety considerations:

Continuous Daily (Most Common)

• Dose every 24 hours
• Typical duration: 4–12 weeks continuously
• Advantage: Consistent blood levels; measurable steady-state effects

• Disadvantage: Potential tachyphylaxis (receptor desensitization) if used >12 weeks
• Recommendation: After 8–12 weeks continuous use, consider 2–4 week washout before re-dosing

Cyclical Administration (5 Days On / 2 Days Off)

• Dose Monday–Friday; skip weekends
• Duration: 8–12 weeks per cycle
• Advantage: Reduces receptor downregulation; may extend effective window
• Disadvantage: Less consistent effects; less data on efficacy

Intermittent (High-Dose Pulse)

• Higher doses (75–100 mcg/kg) 2–3 times weekly
• Duration: 4–8 weeks
• Rationale: May maximize anti-inflammatory or immunomodulatory effects while reducing cumulative exposure
• Consideration: No human data supports this approach; largely theoretical

Washout Periods:

• After 8–12 weeks continuous dosing, recommend 2–4 week break
• Allows receptor upregulation and assessment of compound effects independent of dosing
• Repeat cycle if desired, but total annual exposure should remain <6 months without medical oversight

Timing Relative to Food & Activity:

• Cortistatin administration independent of meals
• For sleep promotion: administer 1–2 hours before bedtime
• For anti-inflammatory goals: time of day less critical; morning or evening acceptable
• Post-injection: avoid strenuous activity for 2 hours (allows absorption)

Beginner vs. Advanced Dosing

Beginner Protocol (First-Time Users)

• Start: 10–20 mcg/kg once daily (subcutaneous)
• Week 1–2: Assess tolerability; monitor for side effects
• Week 3–4: Increase to 30–40 mcg/kg if well-tolerated
• Week 5–8: Maintain 40–50 mcg/kg dose; observe therapeutic effects
• Duration: 8 weeks, then reassess
• Goal: Establish baseline tolerance and response

Intermediate Protocol (Previous Use)

• Start: 40–60 mcg/kg once daily
• Week 1–4: Maintain dose; establish steady-state
• Week 5–8: Consider dose increase to 60–80 mcg/kg if goals not met
• Duration: 10–12 weeks per cycle
• Monitoring: Track specific biomarkers (inflammatory cytokines, HPA axis markers, sleep quality)

Advanced Protocol (Optimized, Multi-Goal)

• Dosing: 50–100 mcg/kg once daily, IV preferred for precision
• Frequency: Daily or 5-on/2-off cycled
• Duration: 12 weeks continuous, followed by 4-week washout
• Stacking: May combine with other research compounds (e.g., somatostatin analogs, ghrelin agonists), though interaction data is limited
• Monitoring: Weekly biomarker tracking; HPA axis, immune panels, sleep architecture

Common Dosing Mistakes

1. Exceeding 100 mcg/kg Without Medical Supervision

• Risk: Bradycardia, excessive sedation, suppression of GH and insulin
• Standard range is 10–100 mcg/kg; do not escalate beyond this without clinical justification

2. Neglecting to Calculate Body Weight-Based Dosing

• Mistake: Using fixed doses (e.g., always 2 mg) regardless of body weight
• Correct approach: Calculate mcg/kg based on actual body weight; recalculate if weight changes

3. Too-Frequent Dose Escalation

• Mistake: Increasing dose every 1–2 weeks chasing faster results
• Correct approach: Allow 3–4 weeks at each dose level before adjustment; steady-state takes time

4. Inadequate Cycle Length

• Mistake: Dosing for only 2–4 weeks then stopping
• Correct approach: Minimum 6–8 weeks per cycle for measurable anti-inflammatory or immunomodulatory effects; up to 12 weeks for cognitive or joint benefits

5. Ignoring Injection Site Rotation

• Risk: Local erythema, abscess formation, necrosis
• Correct approach: Rotate injection sites; use different body areas (abdomen, thighs, arms) each injection

6. IV Administration Without Training

• Risk: Extravasation, thrombophlebitis, infection, air embolism
• Requirement: IV dosing should only be performed by trained medical personnel in clinical/research settings

7. Combining with Unvetted Compounds

• Risk: Unknown drug interactions; cortistatin's interaction profile outside basic research is not characterized
• Recommendation: Do not stack with other experimental peptides or compounds without consulting literature

8. Continuing Beyond Recommended Duration

• Risk: Receptor downregulation; tachyphylaxis; unknown long-term toxicity
• Recommendation: Limit continuous use to 12 weeks; incorporate washout periods before re-dosing

Dosing Summary Table

Summary & Important Disclaimers

Cortistatin dosing ranges from 10–100 mcg/kg once daily via injection, with specific dose selection depending on research goals, experience level, and individual tolerance. Beginners should start at the lower end (10–20 mcg/kg), advancing in 10–20 mcg/kg increments over 3–4 weeks. Intermediate and advanced users typically maintain 40–100 mcg/kg doses for 6–12 week cycles followed by washout periods.

Critical Safety Notes:

• Cortistatin is not approved for human use and remains an investigational compound
• No robust human safety or pharmacokinetic data exist; self-administration carries unknown risks
• Common side effects include transient hypotension (IV), bradycardia (high doses), excessive sedation, GH/insulin suppression, and injection site irritation
• This content is educational only and does not constitute medical or professional advice
• Cortistatin should only be used in supervised clinical research settings or under the guidance of a qualified physician
• Do not self-administer cortistatin outside of IRB-approved studies without informed consent and medical oversight

Consult a qualified healthcare provider or research physician before considering cortistatin use. The dosing information presented here is derived from animal studies and extremely limited human research; direct application to human dosing remains speculative and potentially unsafe.